2.9700 0.00 (0.00%)
After hours: 7:14PM EDT
|Bid||2.9300 x 36200|
|Ask||2.9700 x 45900|
|Day's Range||2.8100 - 3.1800|
|52 Week Range||2.1400 - 18.5000|
|Beta (3Y Monthly)||2.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.47|
Endo International and Allergan could avoid going to trial in a landmark case out of Ohio accusing pharmaceutical companies of marketing practices that preceded the opioid epidemic.
Endo International Plc and Allergan Plc have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic. The tentative deals disclosed on Tuesday came ahead of the first trial to result from 2,000 lawsuits pending in federal court in Cleveland largely by local governments seeking to hold drug companies responsible for the deadly epidemic. Endo announced said it had reached an agreement-in-principle to pay Cuyahoga and Summit counties $10 million to and provide them up to $1 million worth of two of its of its drug products free of charge.
Shares of Endo International PLC soared 30% in active morning trading Tuesday, after the generic drug maker said it has reached a "settlement in principle" to resolve "track 1" opioid cases. Trading volume rose to over 7.6 million shares, already more than the full-day average of about 6 million shares. As part of the settlement, Endo will pay $10 million and provide up to $1 million of its Vasostrict and Adrenalin products free of charge. Endo said the settlement includes no admission of wrongdoing, fault or liability, and is based solely on the avoidance of litigation risk and associated costs. Endo said its subsidiaries involved in the settlement include Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical Inc. and Par Pharmaceuticals Companies Inc., while the plaintiffs are the County of Cuyahoga, Ohio and the County of Summit Ohio. "This is a favorable outcome for the Company," said Endo Chief Legal Officer Matthew Maletta. "As context, the cash portion of the settlement approximates the estimated cost to Endo of proceeding through trial while the product portion of the settlement illustrates the importance of Endo's critical care products." The stock has still tumbled 55% year to date, while S&P 500 has gained 16%.
Endo's stock price surges after the company announces a settlement with Cuyahoga and Summit counties, removing the company from a potentially damaging trial in state court in October.
Allergan is said to be discussing paying $5 million while Endo is close to an agreement to pay $10 million, according to a report.
Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.
NEW YORK, NY / ACCESSWIRE / August 6, 2019 / Endo International Plc (NASDAQ: ENDP ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 6, 2019 at 7:30 ...
Endo (ENDP) delivered earnings and revenue surprises of 10.64% and 0.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Operating Performance Led by Year-over-Year Double-Digit-Percentage Growth in Revenues of Sterile Injectables Segment and Specialty Products Portfolio of Branded Pharmaceuticals Segment - - Endo Reaffirms ...
In March 2019 , the FDA determined that there is no clinical need to compound vasopressin under Section 503B of the Drug Quality and Security Act. As a result, it is unlawful for outsourcing facilities to sell compounded vasopressin products unless they manufacture those products using an FDA-approved vasopressin product, rather than bulk vasopressin, or if vasopressin were to be added to the FDA's drug shortage list. Par Sterile Products, LLC ("Par"), a subsidiary of Endo, is the manufacturer of Vasostrict®, the only vasopressin product approved by the FDA. Following the FDA's decision, Athenex, Inc. and two of its affiliates sued the FDA seeking to overturn the vasopressin decision. Par and another Endo subsidiary intervened as defendants in the action. "At Endo, delivering high quality products and ensuring patient safety are our top priorities and we are very pleased with the district court's decision confirming the FDA's determination that there is no clinical need to bulk compound vasopressin," said Matthew J. Maletta , Executive Vice President and Chief Legal Officer of Endo.
DUBLIN , Aug. 1, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today the appointment of Domenic Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics, ...